In vivo visualization of somatostatin receptor expression with Ga-68-DOTA-TATE PET/CT in advanced metastatic prostate cancer

Alonso Núñez, Omar; Gambini, Juan; Quagliata, Adriana; Lago, G; Gaudiano, J; Engler, H.
Clin Nucl Med ; 36(11): 1063-1064, Nov. 2011.
Artículo en Inglés | BVSNACUY | ID: bnu-16363

Documentos relacionados

  1. Noninvasive longitudinal PET/CT imaging of CAR T cells using PSMA reporter gene.
  2. The Emerging Role of Next-Generation Imaging in Prostate Cancer.
  3. Determining the optimal pharmacokinetic modelling and simplified quantification method of [<sup>18</sup>F]AlF-P16-093 for patients with primary prostate cancer (PPCa).
  4. Preclinical Evaluation of a Fibroblast Activation Protein and a Prostate-Specific Membrane Antigen Dual-Targeted Probe for Noninvasive Prostate Cancer Imaging.
  5. Hot needles can confirm accurate lesion sampling intraoperatively using [<sup>18</sup>F]PSMA-1007 PET/CT-guided biopsy in patients with suspected prostate cancer.
  6. Radiochemistry and In Vivo Imaging of [<sup>45</sup>Ti]Ti-THP-PSMA.
  7. Clinical significance of atypical <sup>68</sup>Ga-DOTATOC prostatic uptake on PET/CT: A ten-year review.
  8. Role of <sup>68</sup>Ga-PSMA PET/CT parameters in treatment evaluation and survival prediction in prostate cancer patients compared with biochemical response assessment.
  9. Combined whole-body dynamic and static PET/CT with low-dose [<sup>18</sup>F]PSMA-1007 in prostate cancer patients.
  10. Infiltrative growth pattern of prostate cancer is associated with lower uptake on PSMA PET and reduced diffusion restriction on mpMRI.